415 related articles for article (PubMed ID: 17949561)
21. Worsening of osteomalacia in a patient successfully treated for neuro-Behçet's disease with infliximab.
Madanat WY; Madanat AY
Clin Exp Rheumatol; 2008; 26(4 Suppl 50):S128-9. PubMed ID: 19026133
[No Abstract] [Full Text] [Related]
22. Successful treatment of genital ulcers with infliximab in Behcet's disease.
Haugeberg G; Velken M; Johnsen V
Ann Rheum Dis; 2004 Jun; 63(6):744-5. PubMed ID: 15140785
[No Abstract] [Full Text] [Related]
23. Successful use of infliximab in a patient with neuro-Behçet's disease.
Abalos-Medina GM; Sánchez-Cano D; Ruiz-Villaverde G; Ruiz-Villaverde R; Quirosa Flores S; Raya Alvarez E
Int J Rheum Dis; 2009 Sep; 12(3):264-6. PubMed ID: 20374357
[TBL] [Abstract][Full Text] [Related]
24. Infliximab treatment for ocular and extraocular manifestations of Behçet's disease.
Accorinti M; Pirraglia MP; Paroli MP; Priori R; Conti F; Pivetti-Pezzi P
Jpn J Ophthalmol; 2007; 51(3):191-6. PubMed ID: 17554481
[TBL] [Abstract][Full Text] [Related]
25. Real-world efficacy of adalimumab and infliximab for refractory intestinal Behçet's disease.
Sugimura N; Mizoshita T; Sugiyama T; Togawa S; Miyaki T; Suzuki T; Tanida S; Kataoka H; Sasaki M
Dig Liver Dis; 2019 Jul; 51(7):967-971. PubMed ID: 30872086
[TBL] [Abstract][Full Text] [Related]
26. Treatment of mucocutaneous manifestations in Behçet's disease with anakinra: a pilot open-label study.
Grayson PC; Yazici Y; Merideth M; Sen HN; Davis M; Novakovich E; Joyal E; Goldbach-Mansky R; Sibley CH
Arthritis Res Ther; 2017 Mar; 19(1):69. PubMed ID: 28335798
[TBL] [Abstract][Full Text] [Related]
27. Effects of anti-TNF-alpha antibody infliximab in refractory entero-Behcet's disease.
Iwata S; Saito K; Yamaoka K; Tsujimura S; Nawata M; Suzuki K; Tanaka Y
Rheumatology (Oxford); 2009 Aug; 48(8):1012-3. PubMed ID: 19465589
[No Abstract] [Full Text] [Related]
28. Anti-Tumor Necrosis Factor Therapy in Intestinal Behçet's Disease.
Park J; Cheon JH
Gut Liver; 2018 Nov; 12(6):623-632. PubMed ID: 29788675
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of infliximab and adalimumab in the treatment of a patient with severe neuro-Behçet's disease.
Belzunegui J; López L; Paniagua I; Intxausti JJ; Maíz O
Clin Exp Rheumatol; 2008; 26(4 Suppl 50):S133-4. PubMed ID: 19026138
[No Abstract] [Full Text] [Related]
30. Behçet's ileocolitis: successful treatment with tumor necrosis factor-alpha antibody (infliximab) therapy: report of a case.
Kram MT; May LD; Goodman S; Molinas S
Dis Colon Rectum; 2003 Jan; 46(1):118-21. PubMed ID: 12544532
[TBL] [Abstract][Full Text] [Related]
31. A case of intestinal Behçet's disease treated with infliximab monotherapy who successfully maintained clinical remission and complete mucosal healing for six years.
Maruyama Y; Hisamatsu T; Matsuoka K; Naganuma M; Inoue N; Ogata H; Iwao Y; Kanai T; Hibi T
Intern Med; 2012; 51(16):2125-9. PubMed ID: 22892489
[TBL] [Abstract][Full Text] [Related]
32. An evaluation of apremilast for the treatment of adult patients with oral ulcers associated with Behçet's syndrome.
Özdede A; Hatemi G
Expert Opin Pharmacother; 2021 Aug; 22(12):1533-1537. PubMed ID: 34218739
[TBL] [Abstract][Full Text] [Related]
33. Refractory Oral Ulcer Responsive to Infliximab: A Case Report.
Ito K; Shikata K; Haba K; Ito T
ORL J Otorhinolaryngol Relat Spec; 2019; 81(4):240-244. PubMed ID: 31256163
[TBL] [Abstract][Full Text] [Related]
34. Behçet's disease - part of the differential diagnosis of ulcerative lesions.
Warren S; Alden K; Lomax N
Int J STD AIDS; 2014 Dec; 25(14):1044-6. PubMed ID: 24676131
[TBL] [Abstract][Full Text] [Related]
35. [Infliximab treatment trial in a patient with neuro-Behçet's disease unresponsive to other treatments].
Kadowaki S; Matsuda N; Moriya A; Ebitani M; Yoshihara A; Nakamura K; Mochizuki H; Ugawa Y
Rinsho Shinkeigaku; 2011 Apr; 51(4):261-6. PubMed ID: 21595295
[TBL] [Abstract][Full Text] [Related]
36. [Six cases with Behcet's disease presenting cervical ulcer].
Huang QS; Chen J; Hou XH; Wang LD; Liu Y
Zhonghua Fu Chan Ke Za Zhi; 2009 Feb; 44(2):112-5. PubMed ID: 19570421
[TBL] [Abstract][Full Text] [Related]
37. Case of neuro-Behçet's disease successfully maintained a remission using infliximab for 2 years.
Kanemaru H; Makino T; Jinnin M; Yonemitsu A; Makino K; Ihn H
J Dermatol; 2013 Aug; 40(8):632-4. PubMed ID: 23724912
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of apremilast for Behçet's syndrome: a real-life single-centre Italian experience.
De Luca G; Cariddi A; Campochiaro C; Vanni D; Boffini N; Tomelleri A; Cavalli G; Dagna L
Rheumatology (Oxford); 2020 Jan; 59(1):171-175. PubMed ID: 31280296
[TBL] [Abstract][Full Text] [Related]
39. Clinical manifestations and anti-TNF alpha therapy of juvenile Behçet's disease in Taiwan.
Hu YC; Yang YH; Lin YT; Wang LC; Yu HH; Lee JH; Chiang BL
BMC Pediatr; 2019 Jul; 19(1):232. PubMed ID: 31296171
[TBL] [Abstract][Full Text] [Related]
40. Remission of intestinal Behçet's disease treated with anti-tumor necrosis factor alpha monoclonal antibody (Infliximab).
Lee JH; Kim TN; Choi ST; Jang BI; Shin KC; Lee SB; Shim YR
Korean J Intern Med; 2007 Mar; 22(1):24-7. PubMed ID: 17427642
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
